



**IHACPA**

**Independent Health and Aged Care Pricing Authority**

**ICD-10-AM/ACHI/ACS  
Twelfth Edition**

**Errata 2**

**For implementation**

**1 October 2022**

## How to use this document

The ICD-10-AM/ACHI/ACS classification system is used for classifying admitted patient care and comprises the following:

- International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM)
- Australian Classification of Health Interventions (ACHI)
- Australian Coding Standards (ACS).

For the published hardcopy books, ICD-10-AM/ACHI/ACS errata may be issued to correct errors and typographical issues that have been identified since the time of publishing. Users are required to incorporate these corrections when using the published hardcopy books.

This document lists corrections to be made to each of the hardcopy books listed in the following order:

- ICD-10-AM Tabular List
- ICD-10-AM Alphabetic Index
- ACHI Tabular List
- ACHI Alphabetic Index
- Australian Coding Standards

Each correction includes:

- The hardcopy book with a page reference
- Instructions to correct codes or terms (eg add, delete, amend)
- The corrected text without track changes detailed in a grey box
- The existing text with track changes detailed in a white box (eg [added text](#), ~~deleted text~~)

### Example of correction

Page #	Add/Delete/Amend <i>Instructional</i> note/code(s)/term(s), and Add/Delete/Amend <i>Instructional</i> note/code(s)/term(s) <i>Corrected text.</i>
<b>CODE</b> ▽ 0000	<b>Code description</b> <del><i>Incorrect</i></del> <i>Corrected</i> <a href="#">text</a> .

## ICD-10-AM Tabular List

<b>Page 46</b>	<b>Add parentheses</b> <i>Excludes:</i> small cell (B-cell) lymphoma (C83.0)
<b>C88.0</b>	<b>Waldenström macroglobulinaemia</b> <i>See subdivisions above</i> Lymphoplasmacytic lymphoma with IgM-production Macroglobulinaemia (idiopathic) (primary)  <i>Excludes:</i> small cell (B-cell) lymphoma (C83.0)
<b>Page 58</b>	<b>Amend Note</b>  <i>Note:</i> Chronic myeloproliferative disorders are classified in ICD-O-3.2 with a malignant behaviour code (/3). Assign codes from category D47 with an appropriate morphology code (regardless of category D47 being located in the Chapter 2 block for <i>Neoplasms of uncertain and unknown behaviour</i> ) — see Alphabetic Index.
<b>D47</b>	<b>Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue</b>  <i>Note:</i> Chronic myeloproliferative disorders are classified in ICD-O-3.2 with a malignant behaviour code (/3). Assign codes from category D47 with an appropriate <del>malignant</del> morphology code (regardless of category D47 being located in the Chapter 2 block for <i>Neoplasms of uncertain and unknown behaviour</i> ) — see Alphabetic Index.
<b>Page 190</b>	<b>Delete Inclusion term</b>  Chronic: • bronchitis NOS • tracheitis • tracheobronchitis
<b>J42</b>	<b>Unspecified chronic bronchitis</b> Chronic: • bronchitis NOS • tracheitis • tracheobronchitis <del>Protracted bacterial bronchitis [PBB]</del>

<b>Page 267</b>	<b>Delete <i>Inclusion</i> terms</b>
N87.0	Mild cervical dysplasia
N87.1	Moderate cervical dysplasia

N87.0	Mild cervical dysplasia <del>Cervical intraepithelial neoplasia [CIN], grade I</del> <del>Low grade squamous intraepithelial lesion (LGSIL)</del>
N87.1	Moderate cervical dysplasia <del>Cervical intraepithelial neoplasia [CIN], grade II</del>

<b>Page 413</b>	<b>Amend <i>Instructional</i> note</b>
	<i>Use additional code (K65.29) to identify secondary peritonitis.</i>

⊕T85.71	Infection and inflammatory reaction due to peritoneal dialysis catheter <i>Use additional code (K65.29) to identify secondary peritonitis.</i>
---------	---

## ICD-10-AM Alphabetic Index

<b>Page 47</b>	<b>Add subterms, and Add nonessential modifier, and Add code</b> - - protracted bacterial (PBB) J41.2
	<b>Bronchitis</b> (15 years of age and above) (diffuse) (fibrinous) (hypostatic) (infective) (membranous) (with tracheitis) — <i>continued</i> ... - in those under 15 years of age ( <i>see</i> <i>also Bronchitis/acute or subacute</i> ) J20.9 - - chronic — <i>see Bronchitis/chronic</i> <a href="#">- - protracted bacterial (PBB) J41.2</a>
<b>Page 55</b>	<b>Add subterm, and Add morphology code</b> - - clear cell (M8310/3)
	<b>Carcinoma</b> (M8010/3) — <i>continued</i> ... - renal (cell) (M8312/3) C64 - - acquired cystic disease associated (M8316/3) - - chromophobe (type) (M8317/3) <a href="#">- - clear cell (M8310/3)</a> - - collecting duct (type) (M8319/3)

**Page 79****Amend codes, and  
Delete subterms, and  
Delete codes**

- confirmed by laboratory testing U07.1-
- virus identified U07.1-

- COVID-19 (coronavirus disease 2019)** (clinically diagnosed) (virus not identified) U07.2
- associated with multisystem inflammatory syndrome U07.5
  - confirmed by laboratory testing ~~U07.12~~ [U07.1-](#)
  - ~~— asymptomatic U07.14~~
  - in pregnancy, childbirth or puerperium O98.5
  - ...
  - virus identified ~~U07.12~~ [U07.1-](#)
  - ~~— asymptomatic U07.14~~

**Page 93****Amend code**

- lymphatic system, congenital Q27.5

- Deformity** — *continued*
- ...
  - lymphatic system, congenital ~~Q89.9~~ [Q27.5](#)

**Page 198****Amend codes**

- - Friedländer's A49.85
- ...
- - - specified A49.89

- Infection, infected** (opportunistic)  
— *continued*
- ...
  - Bacillus, bacillus NEC A49.9
  - - anthracis (*see also Anthrax*) A22.9
  - - Ducrey's (any location) A57
  - - Flexner's A03.1
  - - fragilis A49.81
  - - - as cause of disease classified to other chapters B96.6
  - - Friedländer's ~~A49.89~~ [A49.85](#)
  - ...
  - bacterial (unspecified agent) NEC (*see also Infection/by site*) A49.9
  - - agent (unspecified site) — *see also Infection/by type of agent*
  - - - resistant to antibiotic  
— *see Resistance, resistant/antibiotic(s)*
  - - - specified ~~A48.8~~ [A49.89](#)

<b>Page 202</b>	<b>Amend code, and Delete subterm, and Delete code</b>
	- SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) U07.1-
	<b>Infection, infected</b> (opportunistic) — <i>continued</i> ... - SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) <del>U07.12</del> <a href="#">U07.1-</a> <del>— asymptomatic U07.14</del>
<b>Page 222</b>	<b>Amend cross references</b>
	- actinic (M8070/0) — <i>see also</i> <i>Neoplasm/skin/benign</i> - arsenical (M8070/0) — <i>see also</i> <i>Neoplasm/skin/benign</i> ... - PUVA (M8070/0) — <i>see also</i> <i>Neoplasm/skin/benign</i>
	<b>Keratosis</b> L57.0 - actinic (M8070/0) — <i>see also</i> <i>Neoplasm/skin/</i> <del>uncertain behaviour</del> <a href="#">benign</a> - arsenical (M8070/0) — <i>see also</i> <i>Neoplasm/skin/</i> <del>uncertain behaviour</del> <a href="#">benign</a> ... - PUVA (M8070/0) — <i>see also</i> <i>Neoplasm/skin/</i> <del>uncertain behaviour</del> <a href="#">benign</a>
<b>Page 227</b>	<b>Add cross reference</b>
	- squamous intraepithelial — <i>see also</i> <i>Neoplasia/intraepithelial/squamous</i>
	<b>Lesion</b> (nontraumatic) ... - squamous intraepithelial — <i>see also</i> <a href="#">Neoplasia/intraepithelial/squamous</a> - - high grade (HGSIL) (HSIL) (M8077/2) — <i>see also</i> <i>Neoplasm/in situ</i> - - low grade (LSIL) (M8077/0) — <i>see also</i> <i>Neoplasm/benign</i>
<b>Page 230</b>	<b>Delete code, and Add codes</b>
	<b>LGSIL (low grade squamous intraepithelial lesion)</b> (M8077/0) D26.0
	<b>LGSIL (low grade squamous intraepithelial lesion)</b> <del>N87.0</del> <a href="#">(M8077/0) D26.0</a>
<b>Page 232</b>	<b>Delete cross reference, and Add code</b>
	<b>LSIL (LGSIL) (low grade squamous intraepithelial lesion)</b> (M8077/0) D26.0
	<b>LSIL (LGSIL) (low grade squamous intraepithelial lesion)</b> (M8077/0) <a href="#">D26.0</a> <del>— <i>see also</i> <i>Neoplasm/benign</i></del>

**Page 234**

**Add cross reference**

--- B-cell (centroblastic) (M9680/3) (see also *Lymphoma/B-cell/diffuse large*) C83.3

**Lymphoma** (malignant) (M9590/3)

— *continued*

...

- diffuse (M9591/3) C83.9

-- histiocytic (M9680/3) C83.9

-- large

--- B-cell ([B-cell subtype](#)) (centroblastic)

(M9680/3) — see also *Lymphoma/B-cell/diffuse large* C83.3

~~--- activated B-cell subtype (M9680/3)~~

~~--- germinal-centre B-cell subtype (M9680/3)~~

~~--- immunoblastic (M9684/3)~~

~~--- primary~~

~~--- central nervous system (M9680/3) C72.9~~

~~--- cutaneous, leg type (M9680/3) C44.7~~

--- cell (cleaved) (noncleaved) (M9680/3) C83.3

**Page 255**

**Delete subterms**

-- cervix, cervical (CIN) (uteri) NEC N87.9

--- glandular (CGIN)

---- high grade (HGCGIN) (M8148/2) D06.0

---- low grade (grade I) (grade II) (LGCGIN) (M8148/0) D26.0

--- grade

---- I (M8077/0) D26.0

---- II (M8077/2) (see also *Neoplasm/in situ*) D06.-

---- III (M8077/2) (see also *Neoplasm/in situ*) D06.-

--- low grade (M8077/0) D26.0

**Neoplasia**

...

- intraepithelial

...

-- cervix, cervical (CIN) (uteri) NEC  
N87.9

--- glandular (CGIN)

---- high grade (HGCGIN)  
(M8148/2) D06.0

---- low grade (grade I) (grade II)  
(LGCGIN) (M8148/0) D26.0

--- grade

---- I (M8077/0) D26.0

---- II (M8077/2) (see also *Neoplasm/  
in situ*) D06.-

---- III (M8077/2) (see also *Neoplasm/  
in situ*) D06.-

~~--- cervix, cervical (CIN) (uteri)~~

--- low grade (M8077/0) D26.0



<b>Page 276</b>	<b>Delete codes</b>				
- prepuce					
-- female .....	C51.1	C79.84	D07.1	D28.0	D39.7
-- male .....	C60.0	C79.83	D07.4	D29.0	D40.7
	<b>Malignant</b>				<b>Uncertain or unknown behaviour</b>
	<b>Primary</b>	<b>Secondary</b>	<b>In situ</b>	<b>Benign</b>	
<b>Neoplasm, neoplastic</b> — <i>continued</i>					
- prepuce .....	<del>C60.0</del>	<del>C79.82</del>	<del>D07.4</del>	<del>D29.0</del>	<del>D40.7</del>
-- female .....	C51.1	C79.84	D07.1	D28.0	D39.7
-- male .....	C60.0	C79.83	D07.4	D29.0	D40.7

<b>Page 307</b>	<b>Add subterm, and Add code</b>
	-- spontaneous K65.11
	<b>Peritonitis</b> (acute) (adhesive) (chronic) (fibrinous) (not known whether primary or secondary) (of undetermined cause) (with effusion) NEC K65.9 ... - bacterial NEC K65.8 <a href="#">-- spontaneous K65.11</a> - bile, biliary K65.24

<b>Page 344</b>	<b>Amend code, and Delete subterm, and Delete code</b>
	<b>SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) U07.1-</b>
	<b>SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) <del>U07.12</del> <a href="#">U07.1-</a> <del>-asymptomatic U07.11</del></b>

**Amend code, and  
Delete subterm, and  
Delete code**

- - - coronavirus 2 (SARS-CoV-2) U07.1-  
...  
- - - coronavirus 2 (SARS-CoV-2) U07.1-

**Syndrome** — *continued*

...  
- respiratory  
-- distress (RDS)  
--- acute (ARDS) (child) J80  
--- adult (ARDS) J80  
--- newborn (idiopathic) P22.0  
-- severe acute (SARS) U04.9  
--- coronavirus 2 (SARS-CoV-2)  
    U07.12 U07.1-  
    ~~asymptomatic U07.11~~  
...  
- severe  
-- acute respiratory (SARS) U04.9  
--- coronavirus 2 (SARS-CoV-2)  
    U07.12 U07.1-  
    ~~asymptomatic U07.11~~

## **ACHI Tabular List**

(This page intentionally left blank)

## ACHI Alphabetic Index

<b>Page 18</b>	<b>Amend code</b> - - with rotator cuff repair 48918-00 [1404]
	<b>Arthroplasty — continued</b> ... - shoulder NEC 90533-00 [1404] - - with rotator cuff repair <del>49818-00</del> <a href="#">48918-00</a> [1404]

## Australian Coding Standards (ACS)

Page 31

Add code

- S39.6 *Injury of intra-abdominal organ(s) with pelvic organ(s)*

0049

### DISEASE CODES THAT MUST NEVER BE ASSIGNED

ICD-10-AM has preserved close links with ICD-10 to ensure that international compatibility is maintained, however not all ICD-10 codes are deemed relevant for the Australian health care setting.

The following codes must never be assigned for inpatient morbidity coding:

- F65.0 *Fetishism*
- F65.1 *Fetishistic transvestism*
- F65.5 *Sadomasochism*
- F65.6 *Multiple paraphilia disorders*
- F90.1 *Hyperkinetic conduct disorder*
- G26\* *Extrapyramidal and movement disorders in diseases classified elsewhere*
- L14\* *Bullous disorders in diseases classified elsewhere*
- L45\* *Papulosquamous disorders in diseases classified elsewhere*
- M09.8-\* *Juvenile arthritis in other diseases classified elsewhere*
- M15.9 *Polyarthrosis, unspecified*
- M16.9 *Coxarthrosis, unspecified*
- M17.9 *Gonarthrosis, unspecified*
- M18.9 *Arthrosis of first carpometacarpal joint, unspecified*
- M19.9- *Arthrosis, unspecified – classify osteoarthritis/arthrosis/osteoarthritis NOS as primary osteoarthritis*
- M99.- *Biomechanical lesions, not elsewhere classified*
- N22.-\* *Calculus of urinary tract in diseases classified elsewhere*
- R65.0 *Systemic inflammatory response syndrome [SIRS] of infectious origin without acute organ failure*
- R65.1 *Severe sepsis*
- [S39.6 \*Injury of intra-abdominal organ\(s\) with pelvic organ\(s\)\*](#)
- T76 *Unspecified effects of external causes*
- Y90.9 *Presence of alcohol in blood, level not specified – see also ACS 0503 Drug, alcohol and tobacco use disorders*
- Y91.- *Evidence of alcohol involvement determined by level of intoxication – see also ACS 0503 Drug, alcohol and tobacco use disorders*
- Z50.2 *Alcohol rehabilitation*
- Z50.3 *Drug rehabilitation*
- Z81.- *Family history of mental and behavioural disorders*

**Amend code range**

- one or more codes from block Z14–Z15 to identify resistance to antimicrobial drugs

**0112****INFECTION WITH DRUG RESISTANT MICROORGANISMS**

...

**CLASSIFICATION**

...

**Infection due to an ESBL producing organism**

Where there is documentation of an infection due to an extended spectrum beta-lactamase (ESBL) producing organism, assign:

- a code for the infection in accordance with ACS 0001 or ACS 0002
- a code from block B95–B96 (if not inherent in the infection code)
- one or more codes from block Z14–Z15~~6~~ to identify resistance to antimicrobial drugs.
- U93 *Extended spectrum beta-lactamase [ESBL] producing organism*

**Amend codes**

- Assign an appropriate code from block **[1882]** (codes 92157-03, 92157-04, 92157-05, 92157-06) to identify the type of vaccine, where vaccination against COVID-19 is administered in the current episode of care.

**0113****CORONAVIRUS DISEASE 2019 (COVID-19)**

...

The following table summarises classification guidelines for COVID-19.

COVID-19 TABLE		
STAGE	CODE/BLOCK/DESCRIPTION	GENERAL GUIDELINES
...		
Prevention	U07.7- <i>Coronavirus disease 2019 [COVID-19] vaccines causing adverse effect in therapeutic use</i>	<ul style="list-style-type: none"> <li>• Assign a code from subcategory U07.7 as a supplementary code to adverse effect and external cause codes for an adverse effect due to a COVID-19 vaccination (see Example 7).</li> </ul>
	<b>[1882]</b> <i>Prophylactic vaccination or inoculation against certain viral diseases</i>	<ul style="list-style-type: none"> <li>• Assign an appropriate code from block <b>[1882]</b> (codes <del>92517-03</del>92157-03, 92157-04, <del>92517-05</del>92157-05, <del>92517-06</del>92157-06) to identify the type of vaccine, where vaccination against COVID-19 is administered in the current episode of care.</li> </ul>